Browsing by Autor "Louis Fox"

Now showing 1 - 4 of 4

Comorbidity, treatment toxicity and satisfaction with cancer care: an international cross-sectional study based on the EORTC PATSAT-C33 and OUT-PATSAT7
(Springer Science+Business Media, 2026) Anne Brédart; Jean-Luc Kop; Omar Shamieh; Louis Fox; Waleed Alrjowb; T. Conroy; Nazim Serdar Turhal; Ignacio Juan Arraras; Renée Bultijnck; Amélie Harle
Phase IV international prospective validation of the EORTC patient satisfaction core questionnaire (EORTC PATSAT-C33) and outpatient module (EORTC OUT-PATSAT7)
(BioMed Central, 2025) Anne Brédart; Jean‐Luc Kop; Omar Shamieh; Louis Fox; Waleed Alrjoub; Thierry Conroy; Nazım Serdar Turhal; Juan Ignacio Arrarás; Renée Bultijnck; Amélie Harle
Phase IV international prospective validation of the EORTC patient satisfaction core questionnaire (EORTC PATSAT-C33) and outpatient module (EORTC OUT-PATSAT7)
(2025) Anne Brédart; Jean‐Luc Kop; Omar Shamieh; Louis Fox; Waleed Alrjowb; Thierry Conroy; Serdar Turhal; Iris Juan; Renée Bultijnck; Amélie Harle
<title>Abstract</title> Background Advances in cancer care require ongoing monitoring of patient satisfaction using rigorous questionnaires. The EORTC Quality of Life Group has cross-culturally developed a patient satisfaction core questionnaire (PATSAT-C33) to be used in any hospital cancer care settings and an outpatient satisfaction module (OUT-PATSAT7) to address specific aspects of ambulatory care. This multi-center international prospective study aimed to validate the PATSAT-C33 and OUT-PATSAT7, including assessing its acceptability. Methods Patients (N = 690) affected by any cancer site or stage equally distributed by age and gender, were enrolled in in- and out-patient cancer settings from 20 institutions, 12 countries and 5 geographic/cultural areas. Among them, 675 completed the PATSAT-C33 alongside the EORTC QLQ-C30, Oberst’s perception of care quality 5-item, and ‘ <italic>intention to recommend the hospital’</italic> 1-item. Among the 532 outpatients, 526 also completed the OUT-PATSAT7. A subset completed a two-week retest (N = 120 & 96 for the PATSAT-C33 & OUT-PATSAT7, respectively) or one-year responsiveness-to-change assessment (RCA) (N = 166 & 155). Comprehensive psychometric testing was performed. Results Full item completion was high (85% & 88%), 83% of patients took ≤ 20 minutes to complete both questionnaires (40 items); 5% of patients required help with understanding questionnaire items. Confirmatory factor analyses evidenced satisfactory fit on the eleven PATSAT-C33 and two OUT-PATSAT7 multi-item scales (CFI/TLI > 0.90; RMSEA < 0.10 and = 0.108, respectively). Internal consistency was good to excellent (all ≥ 0.80); test-retest reliability was fair (0.48, 1 scale), good (0.60–0.74, 11 scales) to excellent (≥ 0.75, 7 scales). Convergent validity was supported by correlations of ≥ 0.40 with related Oberst’s scales and < 0.30 with unrelated QLQ-C30 scales. Known-groups differences was shown for comorbidity, toxicity, global health, care expectations and intention to recommend the hospital. Change over time was captured in groups defined based on change in global health, cancer care setting, and the receipt of supportive care over the past year. Conclusions This study supports the psychometric robustness of the EORTC PATSAT-C33 and OUT-PATSAT7 and their promising usefulness in monitoring cancer care within and across cancer care settings from different cultures and cancer patient populations. Trial registration ClinicalTrials.gov ID NCT05989191, released August 2, 2023.
Supportive cancer care and patient satisfaction: international prospective longitudinal study – secondary data analysis
(BMJ, 2026) Anne Brédart; Jean‐Luc Kop; Omar Shamieh; Louis Fox; Waleed Alrjoub; T. Conroy; Nazim Serdar Turhal; J.I. Arraras; Renée Bultijnck; Amélie Harle
International audience